https://doi.org/10.4081/monaldi.2024.2972
Lipid-lowering therapy in patients with coronary heart disease: an Italian real-life survey. Results from the Survey on Risk FactOrs and CardiovascuLar secondary prEvention and drug strategieS (SOFOCLES) in Italy
Submitted: March 1, 2024
Accepted: June 17, 2024
Published: September 10, 2024
Accepted: June 17, 2024
Abstract Views: 454
PDF_EARLY VIEW: 196
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In patients at high cardiovascular risk, a low-density lipoprotein cholesterol (LDL-C) reduction of ≥50% from baseline and an LDL-C goal of <70 mg/dL (or <55 mg/dL in very high-risk patients) are recommended. Multiple registry and retrospective studies have shown that patients with high atherosclerotic cardiovascular risk often do not reach the targets defined by the European Society of Cardiology guidelines as a result of suboptimal management of LDL-C. Here, we report the data on lipid-lowering therapy and lipid targets from the Survey on Risk FactOrs and CardiovascuLar secondary prEvention and drug strategieS (SOFOCLES), an observational, prospective study designed to collect data on patients with ischemic heart disease treated at cardiac outpatient clinics across the Italian national territory. We included patients with known coronary heart disease (CHD) who underwent follow-up visits at various outpatient cardiology clinics. A total of 2532 patients were included (mean age: 67±17 years, 80% male). Among patients with available laboratory data (n=1712), 995 (58%) had LDL-C<70 mg/dL, 717 (42%) had LDL-C≥70 mg/dL, and 470 (27%) had LDL-C<55 mg/dL. Patients who more frequently achieved the recommended LDL-C levels were male, had diabetes, had a higher educational level, and performed intense physical activity. Statins were used in 2339 (92%) patients, high-intensity statins (e.g., rosuvastatin 20/40 mg or atorvastatin 40/80 mg) in 1547 patients (61% of the whole population and 66% of patients on statins), and ezetimibe in 891 patients (35%). Patients receiving high-intensity statins tended to be younger, not to have diabetes, and to have been included in a cardiac rehabilitation program. In a real-world sample of Italian patients with CHD, adherence to lipid-lowering therapy fell markedly short of optimal levels. Many patients did not achieve the LDL-C target of 70 mg/dL, and even fewer reached the LDL-C target of 55 mg/dL. Notably, patients with a lower educational level had a greater likelihood of being undertreated. Strategies aimed at improving preventive interventions for CHD and overcoming social disparities should be evaluated and optimized.
Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971;74:1-12.
DOI: https://doi.org/10.7326/0003-4819-74-1-1
Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-30.
DOI: https://doi.org/10.1093/eurheartj/ehz962
Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
DOI: https://doi.org/10.1016/S0140-6736(12)60367-5
Tobert JA. LDL cholesterol – how low can we go?. Endocrinol Metab Clin North Am 2022;51:681-90.
DOI: https://doi.org/10.1016/j.ecl.2022.01.005
Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
DOI: https://doi.org/10.1016/S0140-6736(10)61350-5
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058.
DOI: https://doi.org/10.1093/eurheartj/ehw272
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88.
DOI: https://doi.org/10.1093/eurheartj/ehz455
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
DOI: https://doi.org/10.1016/S0140-6736(94)90566-5
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
DOI: https://doi.org/10.1056/NEJMoa050461
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.
DOI: https://doi.org/10.1056/NEJMoa1410489
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the statin residual cardiovascular disease risk and peroxisome proliferator-activated receptor alpha agonists and ezetimibe for its treatment. Int J Mol Sci 2022;23:3418.
DOI: https://doi.org/10.3390/ijms23073418
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097-107.
DOI: https://doi.org/10.1056/NEJMoa1801174
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
DOI: https://doi.org/10.1056/NEJMoa1615664
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-19.
DOI: https://doi.org/10.1056/NEJMoa1912387
Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016;7:13457.
DOI: https://doi.org/10.1038/ncomms13457
Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388:1353-64.
DOI: https://doi.org/10.1056/NEJMoa2215024
De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285:135-46.
DOI: https://doi.org/10.1016/j.atherosclerosis.2019.03.014
Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279-89.
DOI: https://doi.org/10.1093/eurjpc/zwaa047
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014;63:2889-934.
DOI: https://doi.org/10.1016/j.jacc.2013.11.002
März W, Dippel FW, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis 2018;268:99-107.
DOI: https://doi.org/10.1016/j.atherosclerosis.2017.11.020
Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur 2023;29:100624.
DOI: https://doi.org/10.1016/j.lanepe.2023.100624
Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011;58:2432-46.
DOI: https://doi.org/10.1161/CIR.0b013e318235eb4d
Tocci G, Ferrucci A, Guida P, et al. Global cardiovascular risk management in different Italian regions: an analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. Nutr Metab Cardiovasc Dis 2012;22:635-42.
DOI: https://doi.org/10.1016/j.numecd.2010.10.009
Ethics Approval
The study was approved by the local ethics committee (NP 2822 – Studio SOFOCLES).How to Cite
Aragona, Caterina Oriana, Andrea Bianco, Roberto Caruso, Massimo Cerulli, Nicola Cosentino, Antonio Cittadini, Michele Gabriele, et al. 2024. “Lipid-Lowering Therapy in Patients With Coronary Heart Disease: An Italian Real-Life Survey. Results from the Survey on Risk FactOrs and CardiovascuLar Secondary PrEvention and Drug StrategieS (SOFOCLES) in Italy”. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2024.2972.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Marta Lazzeri, Andrea Lanza, Raffaella Bellini, Angela Bellofiore, Simone Cecchetto, Alessia Colombo, Francesco D'Abrosca, Cesare Del Monaco, Giuseppe Gaudiello, Mara Paneroni, Emilia Privitera, Mariangela Retucci, Veronica Rossi, Martina Santambrogio, Maurizio Sommariva, Pamela Frigerio, Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR) , Monaldi Archives for Chest Disease: Vol. 90 No. 1 (2020)
- The Publisher, Correction. Robotic resection of mediastinal left vagus neurofibroma , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Mamta Singh, Kunal Deokar, Bibhuti Prassan Sinha, Monika Keena, Govind Desai, Ocular manifestations of common pulmonary diseases: a narrative review , Monaldi Archives for Chest Disease: Vol. 94 No. 1 (2024)
- Mehmet Erdem Çakmak, Saltuk Buğra Kaya, Özge Can Bostan, Ebru Damadoğlu, Gül Karakaya, Ali Fuat Kalyoncu, Short- and long-term oral steroid therapy in patients with asthma exacerbation , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Nikhilesh Ladha, Pankaj Bhardwaj, Nishant Kumar Chauhan, Kikkeri Hanumantha Setty Naveen, Vijaya Lakshmi Nag, Dandabathula Giribabu, Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Gian Marco Rosa, Andreina D'Agostino, Stefano Giovinazzo, Giovanni La Malfa, Paolo Fontanive, Mario Miccoli, Frank Lloyd Dini, Echocardiography of right ventricular-arterial coupling predicts survival of elderly patients with heart failure and reduced to mid-range ejection fraction , Monaldi Archives for Chest Disease: Vol. 90 No. 2 (2020)
- Vinnie Sarah Ch Sangma, Surabhi Jaggi, Varinder Saini, Deepak Aggarwal, Pankaj Kumar, Jagdish Chander, Prevalence of latent tuberculosis infection in household contacts of pulmonary tuberculosis, time to treat , Monaldi Archives for Chest Disease: Vol. 94 No. 1 (2024)
- Vasiliki Epameinondas Georgakopoulou, Nikolaos Garmpis, Dimitrios Mermigkis, Christos Damaskos, Serafeim Chlapoutakis, Konstantinos Mantzouranis, Aikaterini Gkoufa, Chrysovalantis Papageorgiou, Anna Garmpi, Sotiria Makrodimitri, Evangelos Diamantis, Pagona Sklapani, Nikolaos Trakas, Xanthi Tsiafaki, Pulmonary adverse events due to immune checkpoint inhibitors: A literature review , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- Ashish Pundhir, Abhishek Jaiswal, Poonam Kushwaha, Akhil Dhanesh Goel, Anju Gahlot, Lakshmi Singh, Manmeet Kaur, A cross-sectional study on COVID-19 vaccine hesitancy in peri-urban areas in Kanpur, Uttar Pradesh, India , Monaldi Archives for Chest Disease: Vol. 94 No. 1 (2024)
- Shayan Shahid, Ali bin Abdul Jabbar, Abdullah Wagley, Muhammad Daniyal Musharraf, Haris Zahid, Syed Muhammad Zubair, Muhammad Irfan, Non-cystic fibrosis bronchiectasis: a retrospective review of clinical, radiological, microbiological and lung function profile at a tertiary care center of low-middle income country , Monaldi Archives for Chest Disease: Early Access
<< < 82 83 84 85 86 87 88 > >>
You may also start an advanced similarity search for this article.
